Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Shares Sold by Walleye Capital LLC

Walleye Capital LLC lowered its stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 69.7% in the third quarter, HoldingsChannel reports. The fund owned 86,641 shares of the company’s stock after selling 199,162 shares during the quarter. Walleye Capital LLC’s holdings in Syros Pharmaceuticals were worth $186,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals in the third quarter valued at approximately $34,000. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Acadian Asset Management LLC grew its stake in shares of Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after buying an additional 17,416 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after buying an additional 163,234 shares during the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Price Performance

NASDAQ SYRS opened at $0.24 on Thursday. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $8.17. The business has a 50 day moving average price of $1.41 and a two-hundred day moving average price of $3.11. The stock has a market cap of $6.57 million, a PE ratio of -0.08 and a beta of 1.34.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the business earned ($1.35) EPS. As a group, sell-side analysts predict that Syros Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Insider Activity

In related news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 12.26% of the company’s stock.

Analyst Ratings Changes

SYRS has been the topic of a number of research analyst reports. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. StockNews.com started coverage on Syros Pharmaceuticals in a research note on Saturday, December 7th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Syros Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $3.33.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.